{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:48Z","timestamp":1780561428232,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Tocilizumab targets the interleukin-6 receptor, and dosing is complex owing to its nonlinear clearance related to target binding. Therefore, tapering tocilizumab requires a different approach than that of tumor necrosis factor inhibitors (TNFi). This study aimed to identify these differences and enable personalized treatment of rheumatoid arthritis (RA) beyond TNFi therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A population pharmacokinetic model of intravenous tocilizumab was developed using data from a randomized controlled trial of dose tapering in patients with RA. Subsequent population-level Monte Carlo and individual Bayesian simulations were performed to create tapering strategies involving dose reduction and interval extension. The target trough concentration of tocilizumab was 5 mg\/L. Finally, the drug savings were compared between the 2 methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The pharmacokinetic of tocilizumab was described with a 2-compartment model with parallel linear (CL 0.20 L\/d) and nonlinear (V<jats:sub>M<\/jats:sub> 5.2 mg\/d, K<jats:sub>M<\/jats:sub> 0.19 mg\/L) elimination. The linear clearance rate and central volume of distribution increased with lean body mass, and men exhibited higher clearance rates than women. The simulated concentration\u2013time profiles demonstrated that, owing to nonlinear clearance, drug concentrations decreased more than dose-proportionally with lower doses. Tapering based on an individual Bayesian approach emerged as the most promising strategy, yielding a 39% reduction in drug use across virtual populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Tapering strategies were developed for intravenous tocilizumab, offering potential application in patients with RA who have reached low disease activity or remission, pending clinical validation. The developed strategies demonstrate that the tapering of tocilizumab should be approached more carefully and in smaller steps than that of TNFi.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001258","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:02:00Z","timestamp":1731002520000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model\u2013Derived Tapering Strategies for Patients With Rheumatoid Arthritis"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-1300","authenticated-orcid":false,"given":"Femke","family":"Hooijberg","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands;"},{"name":"Department of Rheumatology, Amsterdam UMC, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P. H.","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Layegh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Leeuw","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands;"},{"name":"Department of Rheumatology, Amsterdam UMC, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands;"},{"name":"R&D, Sanquin Diagnostic Services, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands;"},{"name":"Department of Rheumatology, Amsterdam UMC, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands;"},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P. C.","family":"Dorlo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University, Uppsala, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Wolbink","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, the Netherlands;"},{"name":"Department of Rheumatology, Amsterdam UMC, Amsterdam, the Netherlands;"},{"name":"Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.39841","article-title":"Brief report: Relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis","volume":"69","author":"Bejan-Angoulvant","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial","volume":"77","author":"l'Ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0091270009350623","article-title":"Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis","volume":"50","author":"Frey","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bph.16269","article-title":"Formation and clearance of TNF\u2013TNF inhibitor complexes during TNF inhibitor treatment","volume":"181","author":"Berkhout","year":"2024","journal-title":"Br J Pharmacol"},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA","volume":"57","author":"Abdallah","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/bcp.13500","article-title":"Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis","volume":"84","author":"Bastida","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00228-020-02925-w","article-title":"Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic\/pharmacodynamic simulations","volume":"76","author":"Bastida","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/FTD.0000000000001168","article-title":"Tocilizumab dose tapering based on a model-based algorithm is feasible in clinical practice: a short communication","volume":"46","author":"Hooijberg","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/03009742.2016.1183039","article-title":"Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study","volume":"46","author":"Kneepkens","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"Karlsson","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm Res"},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1023\/A:1016215116835","article-title":"Population pharmacokinetic modeling: the importance of informative graphics","volume":"12","author":"Ette","year":"1995","journal-title":"Pharm Res"},{"key":"R21-20250509","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsb.2006.10.003","article-title":"Bootstrap resampling for voxel-wise variance analysis of three-dimensional density maps derived by image analysis of two-dimensional crystals","volume":"158","author":"Cheng","year":"2007","journal-title":"J Struct Biol"},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R25-20250509","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"R27-20250509","doi-asserted-by":"crossref","first-page":"e002035","DOI":"10.1136\/rmdopen-2021-002035","article-title":"Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study","volume":"8","author":"Boekel","year":"2022","journal-title":"RMD Open"},{"key":"R28-20250509","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R29-20250509","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R30-20250509","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(89)80008-0","article-title":"Regulation of interleukin-6 receptor expression in human monocytes and hepatocytes","volume":"249","author":"Bauer","year":"1989","journal-title":"FEBS Lett"},{"key":"R31-20250509","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"R32-20250509","doi-asserted-by":"crossref","first-page":"1759720X211015006","DOI":"10.1177\/1759720X211015006","article-title":"Body composition in patients with rheumatoid arthritis: a narrative literature review","volume":"13","author":"Letarouilly","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R33-20250509","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"R34-20250509","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/0091270012437585","article-title":"Exposure-exposure relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis","volume":"53","author":"Levi","year":"2013","journal-title":"J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:26Z","timestamp":1746792026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001258","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"2024-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}